TXG — 10x Genomics, Inc.

10X Genomics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $149 million, exceeding the top end of guidance, down 2% year-over-year but up 2% sequentially (excluding one-time revenue from Q2).
• Consumables Revenue: $127.9 million, up 1%.
  • Chromium Consumables: $92.5 million, down 4% due to lower average selling prices.
  • Spatial Consumables: $35.4 million, up 19%, driven by strong demand for Xenium.
• Instrument Revenue: $12 million, down 37%.
• Services Revenue: $8.1 million, up 29%.
• Gross Profit: $100.3 million; Gross Margin decreased to 67% from 70% due to product mix changes and higher inventory write-downs.
• Operating Loss: $32.2 million, improved from a loss of $41.5 million in Q3 2024.
• Net Loss: $27.5 million, improved from a loss of $35.8 million in Q3 2024.
• Cash Position: $482 million, up $35 million from the previous quarter.

2. Strategic Updates and Business Highlights

• Continued momentum in single-cell and spatial biology products, particularly with the Xenium platform.
• Launched next-generation Chromium Flex, enhancing scalability and automation-friendly workflows.
• Introduced Xenium protein, enabling simultaneous RNA and protein detection in a single run, streamlining workflows.
• Strong customer feedback on product performance, particularly for the Xenium platform.
• Partnership with Anthropic to enhance data analysis accessibility through AI integration.

3. Forward Guidance and Outlook

• Q4 Revenue Guidance: Expected to be between $154 million and $158 million, reflecting a 5% growth at the midpoint compared to Q3.
• Anticipates continued cautious spending behavior from customers, particularly in capital expenditures, with no expected year-end budget flush.
• Management remains confident in the ability to navigate the macro environment and invest in innovation for long-term growth.

4. Bad News, Challenges, or Points of Concern

• Revenue Declines: Overall revenue down 2% year-over-year; specific declines in Chromium consumables and instruments.
• Market Conditions: Ongoing funding pressures and policy uncertainty affecting customer spending, particularly in the U.S. academic and government sectors.
• Instrument Revenue Decline: Significant drop in instrument sales, down 37%, attributed to lower average selling prices.
• Single-Cell Consumables: Although reaction volumes increased, revenue was impacted by pricing headwinds from new lower-cost products.

5. Notable Q&A Insights

• Management noted that while spatial consumables are performing well, the transition to lower-cost products may create short-term revenue challenges.
• There is a growing preference for the Xenium platform over Visium, indicating a shift in customer dynamics.
• The integration of Scale technology is expected to enhance product offerings but will have minimal near-term revenue impact.
• The company is cautious about the impact of potential government shutdowns on their business, particularly concerning NIH funding.
• There is optimism regarding the long-term potential of single-cell and spatial technologies, especially in translational research and clinical applications.

Overall, while 10X Genomics demonstrated resilience and innovation in Q3 2025, it faces challenges from macroeconomic conditions and pricing pressures that could impact future growth.